Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 208

1.

TGF-β-induced fibrotic stress increases G-quadruplex formation in human fibroblasts.

Toshniwal P, Nguyen M, Guédin A, Viola H, Ho D, Kim Y, Bhatt U, Bond CS, Hool L, Hurley LH, Mergny JL, Fear M, Wood F, Iyer SK, Smith NM.

FEBS Lett. 2019 Nov;593(22):3149-3161. doi: 10.1002/1873-3468.13658. Epub 2019 Nov 15.

PMID:
31677274
2.

Small-Molecule-Targeting Hairpin Loop of hTERT Promoter G-Quadruplex Induces Cancer Cell Death.

Song JH, Kang HJ, Luevano LA, Gokhale V, Wu K, Pandey R, Sherry Chow HH, Hurley LH, Kraft AS.

Cell Chem Biol. 2019 Aug 15;26(8):1110-1121.e4. doi: 10.1016/j.chembiol.2019.04.009. Epub 2019 May 30.

PMID:
31155510
3.

Intracellular speciation of gold nanorods alters the conformational dynamics of genomic DNA.

Ho D, Kretzmann JA, Norret M, Toshniwal P, Veder JP, Jiang H, Guagliardo P, Munshi AM, Chawla R, Evans CW, Clemons TD, Nguyen M, Kretzmann AL, Blythe AJ, Saunders M, Archer M, Fitzgerald M, Keelan JA, Bond CS, Kilburn MR, Hurley LH, Smith NM, Iyer KS.

Nat Nanotechnol. 2018 Dec;13(12):1148-1153. doi: 10.1038/s41565-018-0272-2. Epub 2018 Oct 8.

PMID:
30297819
4.

HMGB1 binds to the KRAS promoter G-quadruplex: a new player in oncogene transcriptional regulation?

Amato J, Madanayake TW, Iaccarino N, Novellino E, Randazzo A, Hurley LH, Pagano B.

Chem Commun (Camb). 2018 Aug 21;54(68):9442-9445. doi: 10.1039/c8cc03614d.

5.

The 3'-end region of the human PDGFR-β core promoter nuclease hypersensitive element forms a mixture of two unique end-insertion G-quadruplexes.

Onel B, Carver M, Agrawal P, Hurley LH, Yang D.

Biochim Biophys Acta Gen Subj. 2018 Apr;1862(4):846-854. doi: 10.1016/j.bbagen.2017.12.011. Epub 2017 Dec 28.

6.

Specific G-quadruplex ligands modulate the alternative splicing of Bcl-X.

Weldon C, Dacanay JG, Gokhale V, Boddupally PVL, Behm-Ansmant I, Burley GA, Branlant C, Hurley LH, Dominguez C, Eperon IC.

Nucleic Acids Res. 2018 Jan 25;46(2):886-896. doi: 10.1093/nar/gkx1122.

7.

Simultaneous Drug Targeting of the Promoter MYC G-Quadruplex and BCL2 i-Motif in Diffuse Large B-Cell Lymphoma Delays Tumor Growth.

Kendrick S, Muranyi A, Gokhale V, Hurley LH, Rimsza LM.

J Med Chem. 2017 Aug 10;60(15):6587-6597. doi: 10.1021/acs.jmedchem.7b00298. Epub 2017 Jul 25.

PMID:
28605593
8.

Insight into the Complexity of the i-Motif and G-Quadruplex DNA Structures Formed in the KRAS Promoter and Subsequent Drug-Induced Gene Repression.

Kaiser CE, Van Ert NA, Agrawal P, Chawla R, Yang D, Hurley LH.

J Am Chem Soc. 2017 Jun 28;139(25):8522-8536. doi: 10.1021/jacs.7b02046. Epub 2017 Jun 15.

9.

The Consequences of Overlapping G-Quadruplexes and i-Motifs in the Platelet-Derived Growth Factor Receptor β Core Promoter Nuclease Hypersensitive Element Can Explain the Unexpected Effects of Mutations and Provide Opportunities for Selective Targeting of Both Structures by Small Molecules To Downregulate Gene Expression.

Brown RV, Wang T, Chappeta VR, Wu G, Onel B, Chawla R, Quijada H, Camp SM, Chiang ET, Lassiter QR, Lee C, Phanse S, Turnidge MA, Zhao P, Garcia JGN, Gokhale V, Yang D, Hurley LH.

J Am Chem Soc. 2017 Jun 7;139(22):7456-7475. doi: 10.1021/jacs.6b10028. Epub 2017 May 19.

10.

Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma.

Liang WS, Hendricks W, Kiefer J, Schmidt J, Sekar S, Carpten J, Craig DW, Adkins J, Cuyugan L, Manojlovic Z, Halperin RF, Helland A, Nasser S, Legendre C, Hurley LH, Sivaprakasam K, Johnson DB, Crandall H, Busam KJ, Zismann V, Deluca V, Lee J, Sekulic A, Ariyan CE, Sosman J, Trent J.

Genome Res. 2017 Apr;27(4):524-532. doi: 10.1101/gr.213348.116.

11.

Identification of G-quadruplexes in long functional RNAs using 7-deazaguanine RNA.

Weldon C, Behm-Ansmant I, Hurley LH, Burley GA, Branlant C, Eperon IC, Dominguez C.

Nat Chem Biol. 2017 Jan;13(1):18-20. doi: 10.1038/nchembio.2228. Epub 2016 Nov 7.

12.

A Mechanosensor Mechanism Controls the G-Quadruplex/i-Motif Molecular Switch in the MYC Promoter NHE III1.

Sutherland C, Cui Y, Mao H, Hurley LH.

J Am Chem Soc. 2016 Oct 26;138(42):14138-14151. doi: 10.1021/jacs.6b09196. Epub 2016 Oct 11.

PMID:
27669098
13.

A Pharmacological Chaperone Molecule Induces Cancer Cell Death by Restoring Tertiary DNA Structures in Mutant hTERT Promoters.

Kang HJ, Cui Y, Yin H, Scheid A, Hendricks WPD, Schmidt J, Sekulic A, Kong D, Trent JM, Gokhale V, Mao H, Hurley LH.

J Am Chem Soc. 2016 Oct 19;138(41):13673-13692. doi: 10.1021/jacs.6b07598. Epub 2016 Oct 5.

PMID:
27643954
14.

Correction to "The Dynamic Character of the BCL2 Promoter i-Motif Provides a Mechanism for Modulation of Gene Expression by Compounds That Bind Selectively to the Alternative DNA Hairpin Structure".

Kendrick S, Kang HJ, Alam MP, Madathil MM, Agrawal P, Gokhale V, Yang D, Hecht SM, Hurley LH.

J Am Chem Soc. 2016 Sep 7;138(35):11408. doi: 10.1021/jacs.6b07292. Epub 2016 Aug 29. No abstract available.

PMID:
27571358
15.

Interaction of Individual Structural Domains of hnRNP LL with the BCL2 Promoter i-Motif DNA.

Roy B, Talukder P, Kang HJ, Tsuen SS, Alam MP, Hurley LH, Hecht SM.

J Am Chem Soc. 2016 Aug 31;138(34):10950-62. doi: 10.1021/jacs.6b05036. Epub 2016 Aug 17.

PMID:
27483029
16.

Molecular population dynamics of DNA structures in a bcl-2 promoter sequence is regulated by small molecules and the transcription factor hnRNP LL.

Cui Y, Koirala D, Kang H, Dhakal S, Yangyuoru P, Hurley LH, Mao H.

Nucleic Acids Res. 2014 May;42(9):5755-64. doi: 10.1093/nar/gku185. Epub 2014 Mar 7.

17.

The transcriptional complex between the BCL2 i-motif and hnRNP LL is a molecular switch for control of gene expression that can be modulated by small molecules.

Kang HJ, Kendrick S, Hecht SM, Hurley LH.

J Am Chem Soc. 2014 Mar 19;136(11):4172-85. doi: 10.1021/ja4109352. Epub 2014 Mar 7.

18.

The dynamic character of the BCL2 promoter i-motif provides a mechanism for modulation of gene expression by compounds that bind selectively to the alternative DNA hairpin structure.

Kendrick S, Kang HJ, Alam MP, Madathil MM, Agrawal P, Gokhale V, Yang D, Hecht SM, Hurley LH.

J Am Chem Soc. 2014 Mar 19;136(11):4161-71. doi: 10.1021/ja410934b. Epub 2014 Mar 7. Erratum in: J Am Chem Soc. 2016 Sep 7;138(35):11408.

19.

DNA structure: Visualizing the quadruplex.

Siddiqui-Jain A, Hurley LH.

Nat Chem. 2013 Mar;5(3):153-5. doi: 10.1038/nchem.1587. No abstract available.

PMID:
23422553
20.
21.

Anticancer activity and cellular repression of c-MYC by the G-quadruplex-stabilizing 11-piperazinylquindoline is not dependent on direct targeting of the G-quadruplex in the c-MYC promoter.

Boddupally PV, Hahn S, Beman C, De B, Brooks TA, Gokhale V, Hurley LH.

J Med Chem. 2012 Jul 12;55(13):6076-86. doi: 10.1021/jm300282c. Epub 2012 Jun 25.

22.

Tertiary DNA structure in the single-stranded hTERT promoter fragment unfolds and refolds by parallel pathways via cooperative or sequential events.

Yu Z, Gaerig V, Cui Y, Kang H, Gokhale V, Zhao Y, Hurley LH, Mao H.

J Am Chem Soc. 2012 Mar 21;134(11):5157-64. doi: 10.1021/ja210399h. Epub 2012 Mar 9.

23.

3-[4-(10H-Indolo[3,2-b]quinolin-11-yl)piperazin-1-yl]propan-1-ol.

Nichol GS, Boddupally PV, De B, Hurley LH.

Acta Crystallogr Sect E Struct Rep Online. 2011 Dec 1;67(Pt 12):o3465-6. doi: 10.1107/S1600536811050215. Epub 2011 Nov 30.

24.

The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer.

Hahn T, Bradley-Dunlop DJ, Hurley LH, Von-Hoff D, Gately S, Mary DL, Lu H, Penichet ML, Besselsen DG, Cole BB, Meeuwsen T, Walker E, Akporiaye ET.

BMC Cancer. 2011 Nov 2;11:471. doi: 10.1186/1471-2407-11-471.

25.

Solution structure of a 2:1 quindoline-c-MYC G-quadruplex: insights into G-quadruplex-interactive small molecule drug design.

Dai J, Carver M, Hurley LH, Yang D.

J Am Chem Soc. 2011 Nov 9;133(44):17673-80. doi: 10.1021/ja205646q. Epub 2011 Oct 14.

26.

Demonstration that drug-targeted down-regulation of MYC in non-Hodgkins lymphoma is directly mediated through the promoter G-quadruplex.

Brown RV, Danford FL, Gokhale V, Hurley LH, Brooks TA.

J Biol Chem. 2011 Nov 25;286(47):41018-27. doi: 10.1074/jbc.M111.274720. Epub 2011 Sep 28.

27.

Targeting G-quadruplexes in gene promoters: a novel anticancer strategy?

Balasubramanian S, Hurley LH, Neidle S.

Nat Rev Drug Discov. 2011 Apr;10(4):261-75. doi: 10.1038/nrd3428. Review.

28.

DNA acting like RNA.

Brown RV, Hurley LH.

Biochem Soc Trans. 2011 Apr;39(2):635-40. doi: 10.1042/BST0390635. Review.

29.

Targeting MYC Expression through G-Quadruplexes.

Brooks TA, Hurley LH.

Genes Cancer. 2010 Jun;1(6):641-649.

30.

The C-terminus of nucleolin promotes the formation of the c-MYC G-quadruplex and inhibits c-MYC promoter activity.

González V, Hurley LH.

Biochemistry. 2010 Nov 16;49(45):9706-14. doi: 10.1021/bi100509s. Epub 2010 Oct 21.

31.

I-motif structures formed in the human c-MYC promoter are highly dynamic--insights into sequence redundancy and I-motif stability.

Dai J, Hatzakis E, Hurley LH, Yang D.

PLoS One. 2010 Jul 19;5(7):e11647. doi: 10.1371/journal.pone.0011647.

32.

The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.

Dietrich J, Hulme C, Hurley LH.

Bioorg Med Chem. 2010 Aug 1;18(15):5738-48. doi: 10.1016/j.bmc.2010.05.063. Epub 2010 Jun 4.

PMID:
20621496
33.

Molecular cloning of the human platelet-derived growth factor receptor beta (PDGFR-beta) promoter and drug targeting of the G-quadruplex-forming region to repress PDGFR-beta expression.

Qin Y, Fortin JS, Tye D, Gleason-Guzman M, Brooks TA, Hurley LH.

Biochemistry. 2010 May 18;49(19):4208-19. doi: 10.1021/bi100330w.

34.

The role of G-quadruplex/i-motif secondary structures as cis-acting regulatory elements.

Kendrick S, Hurley LH.

Pure Appl Chem. 2010 Jan 1;82(8):1609-1621.

35.
36.

Application of a novel [3+2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFG-out allosteric B-Raf inhibitors.

Dietrich J, Gokhale V, Wang X, Hurley LH, Flynn GA.

Bioorg Med Chem. 2010 Jan 1;18(1):292-304. doi: 10.1016/j.bmc.2009.10.055. Epub 2009 Nov 11.

PMID:
19962319
37.

The c-MYC NHE III(1): function and regulation.

González V, Hurley LH.

Annu Rev Pharmacol Toxicol. 2010;50:111-29. doi: 10.1146/annurev.pharmtox.48.113006.094649. Review.

PMID:
19922264
38.

The i-motif in the bcl-2 P1 promoter forms an unexpectedly stable structure with a unique 8:5:7 loop folding pattern.

Kendrick S, Akiyama Y, Hecht SM, Hurley LH.

J Am Chem Soc. 2009 Dec 9;131(48):17667-76. doi: 10.1021/ja9076292.

39.

The role of supercoiling in transcriptional control of MYC and its importance in molecular therapeutics.

Brooks TA, Hurley LH.

Nat Rev Cancer. 2009 Dec;9(12):849-61. doi: 10.1038/nrc2733. Epub 2009 Nov 12. Review.

PMID:
19907434
40.

Modulating the functional contributions of c-Myc to the human endothelial cell cyclic strain response.

Hurley NE, Schildmeyer LA, Bosworth KA, Sakurai Y, Eskin SG, Hurley LH, McIntire LV.

J Vasc Res. 2010;47(1):80-90. doi: 10.1159/000235928. Epub 2009 Sep 3.

41.

Characterization of novel diaryl oxazole-based compounds as potential agents to treat pancreatic cancer.

Shaw AY, Henderson MC, Flynn G, Samulitis B, Han H, Stratton SP, Chow HH, Hurley LH, Dorr RT.

J Pharmacol Exp Ther. 2009 Nov;331(2):636-47. doi: 10.1124/jpet.109.156406. Epub 2009 Aug 5.

42.
43.

Orally active alpha-tocopheryloxyacetic acid suppresses tumor growth and multiplicity of spontaneous murine breast cancer.

Hahn T, Fried K, Hurley LH, Akporiaye ET.

Mol Cancer Ther. 2009 Jun;8(6):1570-8. doi: 10.1158/1535-7163.MCT-08-1079. Epub 2009 Jun 9.

44.

NM23-H2 may play an indirect role in transcriptional activation of c-myc gene expression but does not cleave the nuclease hypersensitive element III(1).

Dexheimer TS, Carey SS, Zuohe S, Gokhale VM, Hu X, Murata LB, Maes EM, Weichsel A, Sun D, Meuillet EJ, Montfort WR, Hurley LH.

Mol Cancer Ther. 2009 May;8(5):1363-77. doi: 10.1158/1535-7163.MCT-08-1093. Epub 2009 May 12.

45.

A direct and nondestructive approach to determine the folding structure of the I-motif DNA secondary structure by NMR.

Dai J, Ambrus A, Hurley LH, Yang D.

J Am Chem Soc. 2009 May 6;131(17):6102-4. doi: 10.1021/ja900967r.

47.

UA62784, a novel inhibitor of centromere protein E kinesin-like protein.

Henderson MC, Shaw YJ, Wang H, Han H, Hurley LH, Flynn G, Dorr RT, Von Hoff DD.

Mol Cancer Ther. 2009 Jan;8(1):36-44. doi: 10.1158/1535-7163.MCT-08-0789.

48.

Psorospermin structural requirements for P-glycoprotein resistance reversal.

Carey SS, Gleason-Guzman M, Gokhale V, Hurley LH.

Mol Cancer Ther. 2008 Nov;7(11):3617-23. doi: 10.1158/1535-7163.MCT-08-0519.

49.

Intramolecularly folded G-quadruplex and i-motif structures in the proximal promoter of the vascular endothelial growth factor gene.

Guo K, Gokhale V, Hurley LH, Sun D.

Nucleic Acids Res. 2008 Aug;36(14):4598-608. doi: 10.1093/nar/gkn380. Epub 2008 Jul 9.

50.

The proximal promoter region of the human vascular endothelial growth factor gene has a G-quadruplex structure that can be targeted by G-quadruplex-interactive agents.

Sun D, Liu WJ, Guo K, Rusche JJ, Ebbinghaus S, Gokhale V, Hurley LH.

Mol Cancer Ther. 2008 Apr;7(4):880-9. doi: 10.1158/1535-7163.MCT-07-2119.

Supplemental Content

Loading ...
Support Center